Claims for Patent: 10,017,536
✉ Email this page to a colleague
Summary for Patent: 10,017,536
Title: | Synthetic peptide amides and dimers thereof |
Abstract: | The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P.sub.450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: ##STR00001## The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. |
Inventor(s): | Schteingart; Claudio D. (San Diego, CA), Menzaghi; Frederique (Rye, NY), Jiang; Guangcheng (San Diego, CA), Alexander; Roberta Vezza (San Diego, CA), Sueiras-Diaz; Javier (La Jolla, CA), Spencer; Robert H. (New Hope, PA), Chalmers; Derek T. (Riverside, CT), Luo; Zhiyong (New City, NY) |
Assignee: | Cara Therapeutics, Inc. (Stamford, CT) |
Application Number: | 15/145,901 |
Patent Claims: |
1. A synthetic peptide amide having the formula: ##STR00127## or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, hydrate, solvate, acid salt
hydrate or N-oxide thereof, wherein p is 1; Xaa.sub.1 is independently selected from the group consisting of (A)(A')D-Phe, (A)(A')(.alpha.-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and
.beta.-(E)D-Ala, wherein each (A) and each (A') are phenyl ring substituents independently selected from the group consisting of --H, --F, --Cl, --NO.sub.2, --CH.sub.3, --CF.sub.3, --CN and --CONH.sub.2, and wherein each (E) is independently selected
from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl; Xaa.sub.2 is independently selected from the group consisting of (A)(A')D-Phe, (A)(A')(.alpha.-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
Xaa.sub.3-Xaa.sub.4-G is selected from one of the following moieties: (i) wherein Xaa.sub.3-Xaa.sub.4- is selected from the group consisting of D-Nle-(B).sub.2D-Arg-, D-Leu-.delta.-(B).sub.2.alpha.-(B')D-Orn-, and
(.alpha.-Me)D-Leu-.delta.(B).sub.2-.alpha.(B')D-Orn-; and G is ##STR00128## and the moiety ##STR00129## is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are
each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and provided that when such ring moiety has a single heteroatom which is N, then such ring moiety
is non-aromatic; and (ii) wherein Xaa.sub.3 is independently selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (.alpha.-Me)D-Leu, D-Hle, D-Val, and D-Met; Xaa.sub.4 is independently selected from the group consisting of
(B).sub.2D-Arg, (B).sub.2D-Nar, (B).sub.2D-Har, .zeta.-(B)D-Hlys, D-Dap, .epsilon.-(B)D-Lys, .epsilon.-(B).sub.2-D-Lys, D-Amf, amidino-D-Amf, .gamma.-(B).sub.2D-Dbu, .delta.-(B).sub.2.alpha.-(B')D-Orn, D-2-amino-3(4-piperidyl)propionic acid,
D-2-amino-3(2-aminopyrrolidyl)propionic acid, D-.alpha.-amino-.beta.-amidino-propionic acid, .alpha.-amino-4-piperidineacetic acid, cis-.alpha.,4-diaminocyclohexane acetic acid, trans-.alpha.,4-diaminocyclohexaneacetic acid,
cis-.alpha.-amino-4-methyl-aminocyclo-hexane acetic acid, trans-.alpha.-amino-4-methylaminocyclohexane acetic acid, .alpha.-amino-1-amidino-4-piperidineacetic acid, cis-.alpha.-amino-4-guanidino-cyclohexane acetic acid, and
trans-.alpha.-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of --H and C.sub.1-C.sub.4 alkyl, and (B') is --H or (.alpha.-Me), and p is zero or 1; and G is ##STR00130## and the moiety
##STR00131## is an optionally substituted 6- or 7-membered heterocyclic ring moiety wherein Y is C or N and Z is C, N, O, S, SO, or SO.sub.2; provided that when such ring moiety is a six-, seven- or eight-membered ring, Y and Z are separated by at least
two ring atoms; provided that when such ring moiety is non-aromatic and Z is C or N then such ring moiety comprises at least one S or O ring heteroatom; and provided further that when such ring moiety is aromatic, then Y is C; wherein W is selected
from the group consisting of: null, provided that when W is null, Y is N; --NH--(CH.sub.2).sub.b-- with b equal to zero, 1, 2, 3, 4, 5, or 6; and --NH--(CH.sub.2).sub.b--O-- with c equal to 2, or 3; wherein V is C.sub.1-C.sub.6 alkyl, and e is zero or
1, wherein when e is zero, then V is null and, R.sub.1 and R.sub.2 are directly bonded to the same or different ring atoms; wherein (a) R.sub.1 is --H, --OH, halo, CF.sub.3, --NH.sub.2, --COOH, C.sub.1-C.sub.6 alkyl, amidino, C.sub.1-C.sub.6
alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, CN, CONH.sub.2, COR', SO.sub.2R', CONR'R'', NHCOR', OR, or SO.sub.2NR'R''; wherein said optionally substituted
heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 alkoxy, oxo, --OH, --Cl, --F, --NH.sub.2, --NO.sub.2, --CN, --COOH, and amidino;
wherein R' and R'' are each independently --H, C.sub.1-C.sub.5 alkyl, aryl, heterocyclyl or R' and R'' are combined to form a 4- to 8-membered ring, which ring is optionally substituted singly or doubly with substituents independently selected from the
group consisting of C.sub.1-C.sub.6 alkyl, --C.sub.1-C.sub.6 alkoxy, --OH, --Cl, --F, --NH.sub.2, --NO.sub.2, --CN, --COOH and amidino; and R.sub.2 is H, amidino, singly or doubly C.sub.1-C.sub.6 alkyl-substituted amidino, --CN, --CONH.sub.2,
--CONR'R'', --NHCOR', --SO.sub.2NR'R'', or --COOH; or (b) R.sub.1 and R.sub.2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and
Z-containing ring moiety; or (c) R.sub.1 and R.sub.2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or (d) R.sub.1 and
R.sub.2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety; wherein
each of said optionally substituted 4- to 9-membered heterocyclic ring moieties comprising R.sub.1 and R.sub.2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C.sub.1-C.sub.6 alkyl,
--C.sub.1-C.sub.6 alkoxy, optionally substituted phenyl, oxo, --OH, --Cl, --F, --NH.sub.2, --NO.sub.2, --CN, --COOH, and amidino; provided that when the Y and Z-containing ring moiety is a six or seven membered ring comprising a single ring heteroatom
and when one of Y and Z is C and the other of Y and Z is N, and e is zero, then R.sub.1 is not --OH, and R.sub.1 and R.sub.2 are not both --H; provided further that when the Y and Z-containing ring moiety is a six membered ring comprising two ring
heteroatoms, both Y and Z are N, W is null, and --V.sub.e(R.sub.1)(R.sub.2) is attached to Z, then --V.sub.e(R.sub.1)(R.sub.2) is selected from the group consisting of amidino, C.sub.1-C.sub.6 alkyl-substituted amidino, dihydroimidazole, --CH.sub.2COOH,
and --H.sub.2C(O)NH.sub.2; and lastly, provided that if the Y and Z-containing ring moiety is a six membered ring comprising an S or O ring heteroatom, or if the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms,
wherein both Y and Z are N and W is null, or if the Y and Z-containing ring moiety is a six membered aromatic ring comprising a single ring heteroatom, which heteroatom is N, then, when e is zero, R.sub.1 and R.sub.2 are not both --H.
2. A method of treating or preventing a kappa opioid receptor-associated disease or condition in a mammal, the method comprising administering to the mammal a composition comprising an effective amount of a synthetic peptide amide according to claim 1, wherein the kappa opioid receptor-associated disease or condition is selected from the group consisting of pain, pancreatitis, pruritis and migraine. 3. The method according to claim 2, wherein the kappa opioid receptor-associated disease or condition is pain. 4. The method according to claim 2, wherein the kappa opioid receptor-associated disease or condition is pancreatitis. 5. The method according to claim 2, wherein the kappa opioid receptor-associated disease or condition is pruritis. 6. The method according to claim 2, wherein the kappa opioid receptor-associated disease or condition is migraine. 7. The method according to claim 2 wherein W is null, G is G(i), Y is N and Z is C. 8. The method according to claim 2 wherein G is G(i) and the Y and Z-containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom. 9. The method according to claim 2 wherein G is G(i) and Y and Z are both N and are the only ring heteroatoms in the Y and Z-containing ring moiety. 10. The method according to claim 9 wherein e is zero and R.sub.1 and R.sub.2 taken together with zero, one or two ring atoms of the Y and Z-containing ring moiety comprise a monocyclic or bicyclic 4-9 membered heterocyclic ring moiety. 11. The method according to claim 9 wherein R.sub.1 and R.sub.2 taken together with one ring atom of the Y and Z-containing ring moiety comprise a 4- to 8-membered heterocyclic ring moiety which with the Y and Z-containing ring moiety forms a spiro structure and W is null. 12. The method according to claim 2 wherein G is G(i) and e is zero and R.sub.1 and R.sub.2 are bonded directly to the same ring atom. 13. The method according to claim 2 wherein G is G(i) and R.sub.1 is H, OH, --NH.sub.2, --COOH, --CH.sub.2COOH, C.sub.1-C.sub.3 alkyl, amidino, C.sub.1-C.sub.3 alkyl-substituted amidino, dihydroimidazole, D-Pro, D-Pro amide, or CONH.sub.2 and wherein R.sub.2 is H, --COOH, or C.sub.1-C.sub.3 alkyl. 14. The method according to claim 2 wherein G is G(i) and the moiety: ##STR00132## is selected from the group consisting of: ##STR00133## ##STR00134## 15. The method according to claim 2 wherein G is G(i) and the moiety: ##STR00135## is selected from the group consisting of: ##STR00136## ##STR00137## 16. The method according to claim 2 wherein G is G(ii) and the moiety ##STR00138## is an optionally substituted 6- or 7-membered heterocyclic ring moiety wherein Y is carbon or nitrogen and Z is carbon, nitrogen, oxygen, sulfur, sulfoxide, or sulfonyl. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.